Cargando…
Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B
BACKGROUND: Immunotherapy of patients suffering from the human epidermal growth factor receptor 2 overexpressing (HER-2(+)) breast cancers with the anti-HER-2 antibodies results in increase of the patients’ overall survival. However, no prophylactic vaccine is available against HER-2(+) breast cance...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990520/ https://www.ncbi.nlm.nih.gov/pubmed/27539579 http://dx.doi.org/10.1186/s40169-016-0111-8 |